Results: The treatment effects on overall survival (OS) for the 482 pts is still significant HR ¼ 0.80 , and similar to the ITT (n ¼ 1226) results (HR ¼ 0.82,. Two established ways of defining mutations (traditional KRAS exon 2 and extended RAS using NGS) show a trend for a differential effect across mutation groups.(see table for OS). Interestingly, BRAF mutants (which are all RAS wild type) show a trend for better outcome Same is seen for PFS and RR. Sidedness did not affect efficacy (HR: 0.83 (0.63-1.1) for left and HR: 0.83 (0.54-1.3) for right. Conclusions: None of the mutations subgroup results shows significant interaction, although the ratios of treatment HR favor RAS wild types. Similar trends were observed in published trials with bevacizumab or ramucirumab. Sanofi supported this ISS.
Background: In contrast to the TRIBE trial, which investigates FOLFIRI/Bevacizumab (bev) þ/À Oxaliplatin, CHARTA was designed to investigate FOLFOX/bev þ/À Irinotecan. For comparison with TRIBE the same treatment protocol and doses as TRIBE have been applied in CHARTA. Methods: The study was powered for an increase of PFS rate @ 9 months from 56% to 68%, with p ¼/< 0.086, requiring 250 patients (pts). Eligibility: ECOG 0-2, ! 1 measurable lesion > 1cm; stratification was done by ESMO-Group 1,2,3. Treatment: Induction for 6 months, followed by maintenance with Capecitabineþ bev. until progression or max.12 months, at progression followed by reinduction (by investigators decision). 25% dose reduction was allowed in cycle 1 þ 2 at the investigator's discretion, with escalation in the following cycles. Randomization from 07/2011 -12/2014, with 250 pts randomised and 241 pts evaluable (1 not elig., 8 prot. violation) after a follow up of 31.4 (0.1-51) months. Pts. characteristics: m/f: 65%/35%, age 61y (21-82), ECOG 0-1/2: 96%/4%. Results: The Primary Endpoint was met: PFS @ 9 months 56% vs. 68%, p ¼ 0.086; PFS 9.8 vs. 12.0 months (HR 0.7, ns.), identical to TRIBE (9.7 vs. 12.1 months). Response rate (A/B): CRþPR 60%/69% (ns), PFS 10.3/12 months (ns), OS 24/28 months (ns). PFS was significantly improved (p ¼ 0.027) in the subgroup of pts. with synchronous metastases (91% of pts); The strongest improvement by the 4 drug combination was shown in those pts. with synchronous mets., who never had resection of the primary (52% of the pts.): 17 vs. 26.5 mos. (p < 0.01). In the subgroup of "liver/lung only" there was no difference, however with a long OS in both arms (45.3 / 44.2 mos.) ESMO groups and Risk Score (Koehne) separated prognostic groups well, however with a different outcome, and less strong for the 4 drug regimen. Univariate prognostic factor analysis identified as significant factors for PFS: ESMO group 1 vs. 2, age <60 and age as continuum, N met. sites, AP </> 300U/l, CEA </> 20ng/ml and synchronous/metachronous metastases. However, in the multivariate model only CEA and syn-/metachr. mets. remained significant; treatment arm was not significant. The CMS-classification analysis is ongoing. Toxicity was low to moderate without major differences except 3 =4 diarrhea (12%/ 16%) and neutrophils (14%/20%). Conclusions: Although not significant, very likely due to the low number of pts., PFS and OS improvement is exactly comparable to TRIBE. In the synchronous metastases-group which represents > 90% of the pts., PFS is significantly improved, mainly driven by the worst subgroup of those pts., who never achieved primary tumor resection. The strongest single prognostic and predictive factor is synchronous vs. metachronous mets. and CEA < 20ng/ml. However, a combination of clinical factors (ESMO groups), lab scores (Risk Score), and CMS classification might be optimal for a combined prognostic and predictive model for better prediction of pts. who have better benefit from the combination. Background: The MAGIC trial established perioperative (periop) epirubicin, cisplatin, and 5-FU (ECF) as a standard treatment for patients (pts) with operable esophagogastric cancer, but survival continues to remain poor. FLOT4 is a multicenter, randomized, investigator-initiated, phase 3 trial. It compares the docetaxel-based triplet FLOT with the anthracycline-based triplet ECF/ECX as a periop. treatment for pts with resectable gastric or GEJ adenocarcinoma. Methods: Eligible pts of stage !cT2 and/or cNþ were randomized to either 3 preoperative and 3 post-operative 3-week cycles of ECF/ECX (epirubicin 50 mg/m
